Literature DB >> 11920913

The active site of human paraoxonase (PON1).

D Josse1, O Lockridge, W Xie, C F Bartels, L M Schopfer, P Masson.   

Abstract

Ideally we would like to treat people exposed to nerve agents with an enzyme that rapidly destroys nerve agents. The enzymes considered for such a role include human butyrylcholinesterase (BChE), acetylcholinesterase (AChE), carboxylesterase and paraoxonase (PON1). Success has been achieved in endowing BChE with the ability to hydrolyze organophosphates. The G117H mutant of BCHE hydrolyzes sarin and VX, whereas the double mutant G117H/E197Q hydrolyzes soman (Millard et al. Biochemistry 1995; 34: 15925-15933; 1998; 37: 237-247). However, the rates of organophosphate hydrolysis are slow and a faster organophosphate hydrolase is being sought. Native PON1 hydrolyzes paraoxon with a catalytic efficiency, of 2.4 x 10(6) M(-1) x min(-1), and our goal is to improve the organophosphate hydrolase activity of PON1. To achieve this we need to identify the amino acids in the active site of PON1. Using site-directed mutagenesis and expression in human 293T cells, we have identified the following eight amino acids as being essential to PON1 activity: W280, H114, H133, H154, H242, H284, E52 and D53. Fluorescence of PON1 complexed to terbium ion shows that at least one tryptophan is close to the calcium binding site. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11920913     DOI: 10.1002/jat.789

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  11 in total

1.  Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization.

Authors:  Amir Aharoni; Leonid Gaidukov; Shai Yagur; Lilly Toker; Israel Silman; Dan S Tawfik
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

2.  Enzymatic detoxification of organophosphorus pesticides and related toxicants.

Authors:  Karla Alejo-González; Erik Hanson-Viana; Rafael Vazquez-Duhalt
Journal:  J Pestic Sci       Date:  2018-02-28       Impact factor: 1.519

3.  Computational characterization of how the VX nerve agent binds human serum paraoxonase 1.

Authors:  Steven Z Fairchild; Matthew W Peterson; Adel Hamza; Chang-Guo Zhan; Douglas M Cerasoli; Wenling E Chang
Journal:  J Mol Model       Date:  2010-04-09       Impact factor: 1.810

4.  Docking and molecular dynamics simulation studies on glycation-induced conformational changes of human paraoxonase 1.

Authors:  Ammara Saleem; S Sikander Azam; Shamshad Zarina
Journal:  Eur Biophys J       Date:  2011-12-23       Impact factor: 1.733

5.  Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization.

Authors:  Su Duy Nguyen; Dai-Eun Sok
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

6.  IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier.

Authors:  Ruben J Boado; Yun Zhang; Yufeng Zhang; Yuntao Wang; William M Pardridge
Journal:  Mol Pharm       Date:  2008 Nov-Dec       Impact factor: 4.939

7.  VX hydrolysis by human serum paraoxonase 1: a comparison of experimental and computational results.

Authors:  Matthew W Peterson; Steven Z Fairchild; Tamara C Otto; Mojdeh Mohtashemi; Douglas M Cerasoli; Wenling E Chang
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

8.  Homology modeling of human serum paraoxonase1 and its molecular interaction studies with aspirin and cefazolin.

Authors:  Mohammed Salman; Chandramouli Malleda; Narayanavari A Suneel; Insaf A Qureshi; Elizabeth A Frank; Cletus Jm D'Souza
Journal:  Bioinformation       Date:  2011-09-06

Review 9.  Human paraoxonase 1 as a pharmacologic agent: limitations and perspectives.

Authors:  Priyanka Bajaj; Rajan K Tripathy; Geetika Aggarwal; Abhay H Pande
Journal:  ScientificWorldJournal       Date:  2014-10-20

10.  Health aspects of organophosphorous pesticides in asian countries.

Authors:  M Balali-Mood; K Balali-Mood; M Moodi; B Balali-Mood
Journal:  Iran J Public Health       Date:  2012-10-01       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.